ArticleRheumatology and therapy2025

A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment.

Xenofon Baraliakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.